Company Monitoring Page for Boehringer-Ingelheim

latest headlines for company on cafepharma

Boehringer, Walgreens Team Up for Obesity Trial as Weight-Loss Drug Race Heats Up
BioSpace
Mon, 05/6/24 - 11:33 am
Tags:
Boehringer Ingelheim, Walgreens, obesity, type 2 diabetes, clinical trials, survodutide
FDA Approval Fuels Boehringer’s Biosimilar Challenge to AbbVie’s Humira
BioSpace
Thu, 05/2/24 - 11:37 am
Tags:
Boehringer Ingelheim, Cyltezo, AbbVie, Huira, FDA, biosimilars
Boehringer signs $1.3B deal with RNA biotech Ochre Bio to team up against MASH
Fierce Biotech
Mon, 04/22/24 - 11:44 am
Tags:
Boehringer Ingelheim, Ochre Bio, RNA, MASH, NASH
Jardiance doesn’t cut it in post-heart attack trial
Pharmaphorum
Mon, 04/8/24 - 11:21 am
Tags:
Boehringer Ingelheim, Eli Lilly, Jardiance, clinical trials, heart attack
Boehringer to lay off salespeople as Humira biosimilar sales lag
Reuters
Fri, 04/5/24 - 11:33 am
Tags:
Boehringer Ingelheim, AbbVie, Humira, biosimilars, layoffs
GSK joins AstraZeneca, Boehringer in capping US out-of-pocket inhaler prices at $35 per month
Fierce Pharma
Thu, 03/21/24 - 06:37 pm
Tags:
GSK, Boehringer Ingelheim, AstraZeneca, drug pricing, COPD, asthma
AstraZeneca follows rival Boehringer in capping out-of-pocket costs for inhalers
Reuters
Mon, 03/18/24 - 11:05 am
Tags:
AstraZeneca, inhalers, drug pricing, Boehringer Ingelheim, Airsupra, Bevespi Aerosphere, Breztri Aerosphere, COPD
Asgard Gets $32M Series A Backing from J&J, Novo and Boehringer
BioSpace
Sun, 03/17/24 - 09:25 pm
Tags:
Asgard Therapeutics, JNJ, Novo Nordisk, Boehringer Ingelheim, funding, immuno-oncology
Boehringer licenses Sosei schizophrenia drugs in €755m deal
Pharmaphorum
Mon, 03/11/24 - 11:40 am
Tags:
Boehringer Ingelheim, schizophrenia, Sosei
Boehringer to cap out-of-pocket inhaler cost at $35 per month
Reuters
Thu, 03/7/24 - 11:08 am
Tags:
Boehringer Ingelheim, drug pricing, Atrovent, Combivent Respimat, Spiriva HandiHale, COPD
Boehringer’s survodutide shows monster MASH potential
Pharmaphorum
Mon, 02/26/24 - 10:36 am
Tags:
Boehringer Ingelheim, weight loss, MASH, NASH, survodutide
Notable Labs hopes for success with Boehringer’s failed AML drug
Clinical Trials Arena
Fri, 02/23/24 - 10:35 am
Tags:
Notable Labs, Boehringer Ingelheim, AML, volasertib, artificial intelligence
Boehringer Ingelheim pledges €120M to expand Greek plant, add capacity for Jardiance
Fierce Pharma
Fri, 01/12/24 - 09:55 am
Tags:
Boehringer Ingelheim, drug manufacturing, Greece, Jardiance
Most extensive cirrhosis £30M study funded by Boehringer Ingelheim
Outsourcing Pharma
Mon, 01/8/24 - 11:26 am
Tags:
Boehringer Ingelheim, liver cirrhosis, funding
Beleaguered Theravance logs head-to-head trial loss for Yupelri against Boehringer's Spiriva
Fierce Pharma
Sun, 01/7/24 - 04:07 pm
Tags:
Theravance, Yupelri, COPD, Boehringer Ingelheim, Spiriva
Boehringer bets $2B in biobucks to unlock siRNA targets for NASH treatments
Fierce Biotech
Wed, 01/3/24 - 09:40 am
Tags:
Boehringer Ingelheim, biobucks, NASH, siRNA, Suzhou Ribo, Ribocure
3 standout digital innovations in pharma this year
Pharma Voice
Mon, 12/4/23 - 09:44 am
Tags:
IDEA Pharma, innovation, digital pharma, AstraZeneca, Roche, Boehringer Ingelheim
Boehringer Ingelheim to collaborate with Phenomic AI on stroma-rich cancers
Medical Marketing and Media
Wed, 11/29/23 - 11:38 pm
Tags:
Boehringer Ingelheim, artificial intelligence, Phenomic AI, stroma-rich cancers
Boehringer plugs in IBM-trained AI model to boost antibody drug discovery efforts
Fierce Biotech
Tue, 11/28/23 - 10:18 am
Tags:
Boehringer Ingelheim, artificial intelligence, IBM, machine learnings, drug discovery
Skyrizi goes sky-high in October among Rx, OTC pharma brands
Medical Marketing and Media
Sun, 11/12/23 - 09:19 pm
Tags:
Boehringer Ingelheim, AbbVie, Skyrizi, DTC advertising, pharma advertising

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.